< Key Hightlight >

MARKET OUTLOOK

Triton’s report on the Alzheimer’s disease therapeutics and diagnostics market in the Middle East and Africa has determined the industry to progress with a CAGR of 4.43% over the forecast period 2021-2028. Turkey, Saudi Arabia, South Africa, the United Arab Emirates, and Rest of Middle East & Africa constitute the market in this region.

Data from the World Population Aging 2019 report, the number of people in South Africa aged 65 years or above was 3.171 million in 2019. This number is expected to rise to 7.920 million by 2050. Thus, the demand for Alzheimer’s disease therapeutics and diagnostics in the country is expected to soar in the coming years. The growing geriatric population, rising burden of the disease, and emerging technologies for the diagnosis & treatment of the disease are collectively driving the growth of the South African market. 

According to a study published in June 2020 major improvements were seen in hospitals with respect to the diagnosis and treatment of dementia and AD in Uganda. This is expected to positively impact the demand for Alzheimer’s disease therapeutics and diagnostics in Rest of Middle East & Africa. Further, in February 2021, a group of researchers from Israel’s Ben-Gurion University developed a new method to diagnosing brain blood vessel pathology, which often leads to neurodegenerative diseases such as Alzheimer’s. Such developments are expected to foster the AD therapeutics and diagnostics market growth in the region.

COMPETITIVE OUTLOOK

Allergan Plc acquired by Abbvie, Novartis AG, Eli Lilly & Company, Johnson & Johnson, PeopleBio Co, Amarantus Bioscience Holdings Inc, Baxter International Inc, Pfizer Inc, Eisai Co Ltd, and Lupin Limited are some of the prominent companies present in the Alzheimer’s disease therapeutics and diagnostics market.